SEC Filing - Acadia Pharmaceuticals Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Baity Glenn

(Last)

(First)

(Middle)

3911 SORRENTO VALLEY BLVD.

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/12/2010

3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
VP, GC & Sec.

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	30,203	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to buy)	⁽¹⁾	07/25/2014	Common Stock	42,000	6.17	D
Stock option (right to buy)	⁽²⁾	03/13/2016	Common Stock	7,000	15.37	D
Stock option (right to buy)	⁽³⁾	03/07/2017	Common Stock	10,000	6.78	D
Stock option (right to buy)	⁽⁴⁾	03/07/2017	Common Stock	6,000	6.78	D
Stock option (right to buy)	⁽⁵⁾	03/06/2018	Common Stock	20,000	8.32	D
Stock option (right to buy)	⁽⁶⁾	10/19/2018	Common Stock	20,000	2	D
Stock option (right to buy)	⁽⁷⁾	10/21/2018	Common Stock	15,000	1.64	D

Explanation of Responses:

1. 25% of the shares subject to the Stock Option vest and become exercisable on July 26, 2005. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

2. 25% of the shares subject to the Stock Option vest and become exercisable on March 14, 2007. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

3. 25% of the shares subject to the Stock Option vest and become exercisable on January 1, 2008. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

4. 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2008. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

5. 25% of the shares subject to the Stock Option vest and become exercisable on March 7, 2009. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

6. 50% of the shares subject to the Stock Option vest and become exercisable on October 20, 2010. The remaining shares vest and become exercisable thereafter in 48 equal monthly installments.

7. 25% of the shares subject to the Stock Option vest and become exercisable on October 22, 2009. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

	/s/ Glenn F. Baity	03/16/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

rrd241890_273028.html

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes Uli Hacksell, Thomas H. Aasen or Kirk V. Crawford to execute for and on behalf of the undersigned, in the undersigned's capacity as a director of ACADIA Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such att
orney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed this 12th day of March 2010.

/s/ Glenn F. Baity
GLENN F. BAITY